Altimmune to test obesity drug for alcohol use disorder and related health conditions
Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...
Zacks Investment Research on MSN16h
NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand
Novo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 ...
Zacks Investment Research on MSN17h
Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update
Novo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche RHHBY announced a license and collaboration deal with Denmark’s Zealand Pharma to co ...
Nepali Times3h
Undernourished to overweight
At the pace with which the proportion of overweight people is growing, half of Nepal’s adult population will be obese by 2050 ...
Medical Marketing & Media18h
Roche strikes $5.3B obesity treatment deal with Zealand Pharma
Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...
Trump’s Chips War Has Left Intel’s New CEO With a Near-Impossible Task
The Dow, S&P 500, and Nasdaq fell Thursday as the stock market digested the latest economic data and Trump's response to Canada and EU tariffs. The S&P 500 closed in correction territory.